

ACHAAGEN

Achaogen Announces Presentation at Investor Healthcare Conference in November

November 9, 2018

SOUTH SAN FRANCISCO, Calif., November 9, 2018 – Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be presenting at the following investor conference:

- Stifel 2018 Healthcare Conference (New York) on November 13th, 2018 at 3:30 p.m. ET

Live audio webcasts of the presentations will be available in the "Investors" section of Achaogen's website, www.achaogen.com. Replays of each presentation will be archived for 30 days following the conference for those unable to listen live.

About Achaogen

Achaogen is a biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen's first commercial product is ZEMDRI, for the treatment of adults with complicated urinary tract infections, including pyelonephritis. The Achaogen ZEMDRI program was funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA). The Company is currently developing C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination, which is also supported by BARDA. C-Scape is investigational, has not been determined to be safe or efficacious, and has not been approved for commercialization. For more information, visit the Achaogen website at www.achaogen.com.

Source: Achaogen, Inc

© 2018 Achaogen, Inc. All Rights Reserved.

Investor and Media Contact:

Martin Forrest

Achaogen, Inc.

mforrest@achaogen.com

650-419-3920